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Abstract
BACKGROUND: Heart failure disease management programs can influence medical resource use and
quality-adjusted survival. Because projecting long-term costs and survival is challenging, a consistent and valid
approach to extrapolating short-term outcomes would be valuable.
METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart
Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic,
clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted
outcomes. Survival projections are based on a modified Seattle Heart Failure Model. Projections of resource
use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.
The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.
Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs,
survival, and incremental cost-effectiveness ratios from user inputs.
RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use,
costs, and survival estimates from 3 clinical trials. Simulations to evaluate the cost-effectiveness of heart failure
disease management programs across 3 scenarios demonstrate how the model can be used to design a
program in which short-term improvements in functioning and use of evidence-based treatments are
sufficient to demonstrate good long-term value to the health care system.
CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure
Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-
effectiveness analyses of disease management programs in heart failure.
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Abstract
Background—Heart failure disease management programs can influence medical resource use 
and quality-adjusted survival. Because projecting long-term costs and survival is challenging, a 
consistent and valid approach to extrapolating short-term outcomes would be valuable.
Methods—We developed the Tools for Economic Analysis of Patient Management Interventions 
in Heart Failure (TEAM-HF) Cost-Effectiveness Model, a Web-based simulation tool designed to 
integrate data on demographic, clinical, and laboratory characteristics, use of evidence-based 
medications, and costs to generate predicted outcomes. Survival projections are based on a 
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modified Seattle Heart Failure Model (SHFM). Projections of resource use and quality of life are 
modeled using relationships with time-varying SHFM scores. The model can be used to evaluate 
parallel-group and single-cohort designs and hypothetical programs. Simulations consist of 10,000 
pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental 
cost-effectiveness ratios from user inputs.
Results—The model demonstrated acceptable internal and external validity in replicating 
resource use, costs, and survival estimates from 3 clinical trials. Simulations to evaluate the cost-
effectiveness of heart failure disease management programs across 3 scenarios demonstrate how 
the model can be used to design a program in which short-term improvements in functioning and 
use of evidence-based treatments are sufficient to demonstrate good long-term value to the health 
care system.
Conclusion—The TEAM-HF Cost-Effectiveness Model provides researchers and providers with 
a tool for conducting long-term cost-effectiveness analyses of disease management programs in 
heart failure.
Introduction
Although economic evaluations of heart failure disease management programs are plentiful, 
a recent review identified only 2 formal cost-effectiveness analyses that extrapolated beyond 
a trial’s follow-up period.1 Without extrapolation, the value of a disease management 
program may be underestimated. For example, an analysis of the South Texas Congestive 
Heart Failure Disease Management Project reported an incremental cost-effectiveness ratio 
greater than $100,000 per quality-adjusted life-year (QALY) within the trial’s 18-month 
follow-up period.2 However, extension of the time horizon with a Markov model structured 
using New York Heart Association (NYHA) classification reduced the incremental cost-
effectiveness ratio to less than $50,000 per QALY.3 This example demonstrates the 
importance of accounting for all downstream costs and health benefits attributable to an 
intervention to provide a fair assessment of its cost-effectiveness.
With support from the National Institute of Nursing Research, we developed user-friendly 
tools to facilitate high-quality economic evaluations of patient-focused interventions. In our 
project, Tools for Economic Analysis of Patient Management Interventions in Heart Failure 
(TEAM-HF), we developed a costing tool4 and a cost-effectiveness model. In this paper, we 
describe the TEAM-HF Cost-Effectiveness Model, a generalizable, Web-based tool 
designed to assist researchers, administrators, and providers in estimating short-term or 
long-term estimates of resource use, costs, and cost-effectiveness of disease management 
programs or other care strategies in heart failure. We then compare predicted estimates of 
resource use and costs from the model to estimates from 3 studies to evaluate the internal 
and external validity of the model. We also evaluate the potential cost-effectiveness of 3 
disease management scenarios to demonstrate how the model can be used to design more 
cost-effective interventions.
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Methods
Web-Based Application
To maximize accessibility, we developed a freely available Web-based tool that allows users 
to select modeling options and specify inputs in an integrated simulation model. The tool 
takes the form of a series of input pages (Table 1). It includes 3 study design options: 
hypothetical scenario; parallel groups; and single cohort (Supplemental Figure A).
The hypothetical scenario design option allows the user to generate simulated outcomes for 
2 patient groups with different clinical and treatment characteristics. The parallel groups 
design option is appropriate for randomized trials or other studies with 2 comparator groups. 
The user prescribes observed counts of resource use and deaths for the observed follow-up 
period. After the observation period, simulated outcomes are generated over the time period 
specified by the user. The single cohort design option allows users to evaluate a program 
that has already been implemented. The user prescribes clinical and treatment characteristics 
for the patients before and after their participation in the program.
Additional input pages correspond to patients’ demographic and clinical characteristics, 
laboratory test results, use of diuretics, and use of evidence-based medications and devices 
that represent parameters in the prognostic model integrated with the tool. The user can also 
prescribe unit costs for medications, hospitalizations, emergency department visits, and 
outpatient visits.
A cost-effectiveness analysis requires users to account for the costs associated with a disease 
management program. Therefore, the user must specify the duration and monthly cost of the 
program. If the program includes an “intense” phase and a less intense “maintenance” phase, 
the user can specify the duration and monthly cost for each phase. The user can also extend 
the monthly costs of the program indefinitely (ie, until death). The final inputs relate to the 
time horizon for the simulations, discount rates, and options for reporting.
Model Structure
We selected the Seattle Heart Failure Model (SHFM) as the underlying prognostic model, 
because its external validity has been tested in 14 clinical cohorts, more than any other 
model for heart failure.5,6 Also, its inclusion of multiple clinical and laboratory variables 
and the integration of treatment effects for evidence-based therapies allows our model to 
account for the effects of disparate disease management programs or treatment care 
strategies. For example, the same model could be used to evaluate a program to improve 
physical functioning or a program to increase the use of β-blockers.
Modifications to the SHFM
In the original SHFM publication, an exponential hazard function was suggested to generate 
long-term survival estimates.5 An exponential hazard function assumes a constant mortality 
rate, which can lead to overestimation of survival. Therefore, we replaced the exponential 
function with a calibrated competing risks regression model in which the baseline hazard for 
each mode of death was assumed to follow a Gompertz distribution, under the proportional 
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hazards assumption, using data representing 7151 patients from 4 clinical trials and 
prospective observational cohorts.6 The shape parameters for heart failure death and non–
heart failure death were positive (0.281 and 0.204, respectively), indicating increasing risk 
over time, whereas the parameter for sudden death was approximately equal to zero (< .001), 
indicating constant risk. The fitted survival model enables us to calculate expected survival 
time for any SHFM score. Figure 1 shows the overall survival curves for integer SHFM 
scores; the corresponding table displays the mean survival estimates. See the Online-Only 
Supplement for details.
We also modified the treatment effects of several medication classes in the SHFM. First, we 
removed the effect of statins on mortality risk to reflect findings from 2 clinical trials.7,8 
Second, although meta-analyses support the benefits of angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs) in heart failure, clinical trials 
have not demonstrated additive treatment effects of ARBs with ACE inhibitors.9–11 
Therefore, we modified the SHFM to apply a hazard ratio of 0.77 for patients treated with an 
ACE inhibitor and/or ARB.12 Third, we reduced the treatment benefit of aldosterone 
antagonists by replacing the hazard ratio of 0.70 from the Randomized Aldactone Evaluation 
Study (RALES) with a hazard ratio of 0.76 from the Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF),13 an effect consistent 
with an earlier meta-analysis.14
Mode of Death
Resource use, associated medical costs, and health-related quality of life in the year before 
death differ markedly between patients who die from sudden death versus other causes.15 To 
account for these differences, we used mathematical relationships derived from data from 
the 4 cohorts described above to estimate the conditional probability of dying from heart 
failure, sudden death, or another cause as a function of time and a patient’s baseline SHFM 
score (Figure 2). We incorporated these probabilities into the model such that the assigned 
cause of death for each virtual patient was conditional on the patient’s initial SHFM score 
and simulated time of death.
Modeling Medical Resource Use and Health Utilities
In addition to estimating survival and assigning a mode of death for each virtual patient, the 
model assigns rates of medical resource use and health utility (ie, quality of life) weights 
across time. We used data from Heart Failure: A Controlled Trial Investigating Outcomes of 
Exercise Training (HF-ACTION) to estimate relationships between SHFM scores and rates 
of medical resource use16 and health utilities.17 As expected, patients with higher SHFM 
scores had significantly higher rates of hospitalization, emergency department or urgent care 
visits, and nonurgent outpatient visits in the following year.16 We assigned cause-specific 
hospitalizations according to distributions observed in HF-ACTION. Similarly, higher 
SHFM scores predicted lower health utilities at baseline, and their mean utilities decreased 
at a faster rate relative to lower SHFM scores.17
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Modeling Change in SHFM Scores
To relate the natural progression of heart failure with corresponding SHFM scores, we used 
mathematical relationships to determine the rate at which SHFM scores would have to 
increase to maintain consistency with the time-varying global hazard function (Online-Only 
Supplement). By quantifying the relationships between initial SHFM scores and SHFM 
scores across time, the model updates each virtual patient’s SHFM score each year. This 
approach allows the model to assign higher rates of resource use and lower health utilities 
over time.
Model Simulations
Simulations consist of 10,000 Monte Carlo iterations. Each iteration represents a single 
realization of the 2 user-defined virtual patient cohorts with sample sizes specified by the 
user. For each virtual patient within a cohort, demographic, laboratory, and clinical 
characteristics are sampled from a multivariate mixed distribution based on user-prescribed 
inputs. The default values and associated correlation matrix were derived from the 4-cohort 
sample of 7151 patients described above (Supplemental Tables B1 and B2).5
For each virtual patient, the simulated time of death is sampled from the corresponding 
SHFM score–specific survival function (Supplemental Figure 3.1). The cause of death is 
then assigned using the cumulative probabilities of death (for heart failure, sudden cardiac 
death, and other cause), conditional on the initial SHFM score and the simulated time of 
death (Figure 2). The SHFM score for each virtual patient is then updated for each 
subsequent year.
Annual counts of medical resources are generated for each virtual patient using negative 
binomial regression models, in which the predicted SHFM score at the beginning of each 
year is the explanatory variable. When less than 1 year of survival remains, the explanatory 
variables in the regression models include the patient’s predicted SHFM score at the 
beginning of that year, the simulated cause of death, and the number of days alive in the 
final year of life (Supplemental Table 5.1). For each simulated year across the 10,000 Monte 
Carlo iterations, unit cost estimates are multiplied by the corresponding counts for each type 
of medical resource for each patient in each cohort. Costs in each year are then discounted 
and summed to calculate cumulative costs for each cohort.
Utility weights are assigned to account for differences in quality of life across patients. Each 
virtual patient’s utility weight is a linear function of the patient’s corresponding time-
adjusted SHFM score. When the user opts to allow utilities to vary (ie, “stochastic” option), 
each virtual patient’s initial utility score is sampled from a normal distribution and then 
decays in a linear fashion until the time of death. In cases for which the sampled utility 
weight exceeds 1, the value is capped at 1.
Variability
The model incorporates stochastic uncertainty, which represents differences in outcomes 
that can occur between 2 realizations of the same patient. For example, a patient with an 
SHFM score of 1.0 may have an estimated life expectancy of 5.14 years, but the sampled 
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life expectancy for 2 simulated patients with the same SHFM score could be 3 months or 8 
years, representing stochastic uncertainty.
The user has the option to select “deterministic” or “stochastic” for SHFM coefficients, time 
of death, resource use, and utility weights. With the deterministic option, expected values for 
resource use, health utilities, and survival are assigned to virtual patients in each of the 
10,000 iterations. With the “stochastic” option, outcomes for each patient are sampled from 
their corresponding parametric distributions in each iteration, resulting in 10,000 estimates 
for resource use, cost, and survival. Corresponding 95% CIs are calculated by sorting the 
10,000 estimates in ascending order and taking the 250th and 9750th ranked values.
Validation
We applied the TEAM-HF Cost-Effectiveness Model to 3 heart failure trials to compare 
simulated and observed estimates and to demonstrate how the model can be used to reverse-
engineer a cost-effective disease management program. The inputs specified in each of the 3 
validation tests are reported in Supplemental Table D.1. We performed the simulations using 
both the stochastic and deterministic options to demonstrate the impacts of these choices.
CHIME
The Medication Adherence in Chronic Illness: Medications, Meaning and Me (CHIME) 
pilot study tested an intervention to improve medication adherence in 86 high-risk patients 
with heart failure.18 The intervention included quarterly phone calls to the patient from a 
nurse. At 1 year, medical resource use and costs were similar across both groups. To 
increase the sample size for validation testing, we combined patients from both groups.
To demonstrate how the model could be used to evaluate the cost-effectiveness of a disease 
management program, we included the 86 patients from CHIME in the standard care group. 
Then, we modeled 3 hypothetical scenarios representing programs that could increase 
proportions of patients in NYHA class II and increase use of evidenced-based medications. 
For program costs in scenario A, we computed the cost per patient per month in CHIME 
using the TEAM-HF Costing Tool.4
Internal Validation in HF-ACTION
Several statistical associations embedded in the TEAM-HF model were derived from HF-
ACTION.19 Thus, comparisons between estimates from the model with estimates from HF-
ACTION represent an internal validation test. Because observed resource use and outcomes 
were similar between groups in the trial, baseline characteristics were pooled across study 
groups and modeled over 2 years.
SCD-HeFT
The economic evaluation of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 
provides an opportunity to compare estimates over a longer time horizon (20). SCD-HeFT 
was a randomized trial of 2521 patients with symptomatic heart failure that found a 
statistically significant reduction in all-cause mortality among patients who received a 
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single-lead implantable cardioverter-defibrillator (ICD), compared with patients who 
received medical therapy or placebo. Median follow-up was 45.5 months.
Funding/Support
Development of the TEAM-HF Cost-Effectiveness Model was supported by grant 
5R01NR011873-02 from the National Institute of Nursing Research. The development and 
content of the TEAM-HF economic tools are solely the responsibility of the authors and do 
not necessarily represent the official views of the National Institute of Nursing Research or 
the National Institutes of Health. The trials used for validation purposes were supported 
separately.
Results
CHIME
In CHIME, patients were hospitalized an average of 1.3 times, had 0.5 emergency 
department visits, and had 3.1 outpatient visits (Table 2). By comparison, our model 
estimated 1.1 hospitalizations, 1.0 emergency department visits, and 13.9 outpatient visits. 
Mean total costs estimated using patient-level data from CHIME were similar to mean total 
costs estimated with the TEAM-HF model ($23,861 vs $23,621) when all levels of 
uncertainty were varied stochastically. When parameter estimates were modeled 
deterministically, the point estimate was $19,622.
To evaluate potential disease management programs, we assumed that the intervention in 
scenario A increased the proportion of patients with NYHA class II by 10 percentage points 
and the use of evidence-based medications increased by 5 percentage points. Intervention 
costs in scenario A included initiation costs of $70 and maintenance costs of $59 per patient 
per month for 1 year. Compared with standard care, mean total costs in scenario A increased 
by $1393 and QALYs increased by 0.2, corresponding to an incremental cost-effectiveness 
ratio of $6128 per QALY (Table 3). Scenarios B and C represent a higher-cost program with 
$2000 initiation costs plus ongoing costs of $200 per patient per month. With the same level 
of effectiveness as scenario A, the incremental cost-effectiveness ratio increased to $64,865 
per QALY in scenario B. However, with greater effectiveness in scenario C, the higher cost 
of the program is offset by greater gains in QALYs (0.4), resulting in an incremental cost-
effectiveness ratio of $29,701 per QALY.
HF-ACTION
Observed estimates of medical resource use in HF-ACTION and estimates from our model 
were similar (Table 4). In HF-ACTION, patients were hospitalized an average of 2.0 times, 
visited the emergency department or urgent care clinic 1.6 times, and had 30.6 outpatient 
visits. Based on the TEAM-HF model, patients would have been expected to have an 
average of 2.1 hospitalizations, 1.9 emergency department or urgent care visits, and 26.3 
outpatient visits. Total costs were also similar between estimates based on empirical data 
($46,361) and modeled estimates ($48,098). Observed survival at 2 years was 83.4% in HF-
ACTION compared to a modeled estimate of 79.6%.
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SCD-HeFT
Five-year estimates of resource use and total costs generated with the TEAM-HF model 
were higher than reported for SCD-HeFT (20) in the ICD and placebo groups (Table 5). 
However, the estimated differences in mean costs at 5 years were similar: $23,472 with the 
TEAM-HF model and $27,141 in SCD-HeFT. Five-year survival predicted with the model 
was 3 to 4 percentage-points lower than reported for SCD-HeFT. Nevertheless, 5-year 
survival gains and incremental cost-effectiveness ratios were similar for ICDs compared 
with standard care.
Discussion
The TEAM-HF Cost-Effectiveness Model provides a flexible tool for the research and 
clinical communities to evaluate the long-term cost-effectiveness of disease management 
programs in heart failure. In addition to facilitating formal cost-effectiveness analyses, the 
model can be used for budget planning, projecting hospitalization rates, and quantifying life 
expectancy for a cohort of patients over a time period specified by the user. For example, the 
model could be used by health systems to predict cost offsets with a given program or to 
demonstrate expected longer-term cost-savings for a payer for a program that increases costs 
in the short-term. The model’s flexibility also offers users the opportunity to represent 
different perspectives by specifying direct medical costs to represent the health care system 
perspective or payments to represent the payer perspective.
We believe ours to be the first generalizable simulation model developed to evaluate clinical 
and economic outcomes of patient-centered programs in heart failure. Previous models were 
developed to evaluate specific interventions and were structured using NYHA class3,21 or 
hospitalization counts as health states.22 Such models are not publicly available and cannot 
account for a broader range of factors that disease management programs may affect. 
Furthermore, variations in methods and reporting hinders the ability to make valid 
comparisons across studies.1,23 With repeated use of a common model by different 
investigators, a collection of studies could develop to provide a body of evidence on which 
types of interventions targeting specific patient groups consistently provide better or worse 
value. In addition, individual stakeholders could apply the model to support local decision 
making by modifying unit costs, patient characteristics, changes in prognostic variables 
affected by an intervention, and the time horizon of interest.
Model Validity
It is not possible to simply declare a model as “valid.”24 There are several types of validity, 
including face validity, internal validity, cross validity (between models), external validity, 
and predictive validity, with the latter 2 types being the strongest. Demonstration of an 
economic model’s external and predictive validity, particularly for resource use and costs, is 
limited by variations in practice patterns and unit costs across settings.24 Furthermore, for a 
model like TEAM-HF that can have multiple applications, numerous validation exercises 
across a range of interventions across various patient populations, outcomes, and time 
horizons may be necessary. In fields such as diabetes, where multi-application simulation 
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models were initially developed more than a decade ago, the relative strengths and 
limitations of these models are only now becoming understood.25
In our examination of the model’s internal validity, we found that modeled estimates of 
resource use and mortality were consistent with empirical estimates from HF-ACTION. The 
findings of the 2 external validation tests were also promising. Our modeled estimates of 
hospitalizations were similar to CHIME, but modeled estimates of emergency department 
and outpatient visits were higher. The discrepancy can be attributed to differences in the 
scope of emergency department and outpatient visits included in the analysis. In CHIME, 
patients reported emergency department visits and outpatient physician visits associated 
with heart failure, whereas the TEAM-HF model includes all-cause visits to all health care 
providers (as collected in HF-ACTION). Compared with claims-based analyses in which all 
outpatient visits are considered (approximately 14 to 20 per year for patients with type 2 
diabetes26; approximately 18 to 22 per year for patients with atrial fibrillation27), the 
TEAM-HF model produces counts of similar magnitude.
SCD-HeFT provided an opportunity to examine the model’s external validity over a longer 
time horizon. Cost data were not available in SCD-HeFT over a 5-year time frame for all 
patients, and partitioned estimators were used to adjust cost estimates to account for 
censoring. Because this approach did not account for higher rates of medical resource use 
that occurs with disease progression, one could expect costs from SCD-HeFT to be lower 
than costs from the model. Although reported 5-year costs in SCD-HeFT were lower than 
predicted with the TEAM-HF model, the CIs from the TEAM-HF model included the point 
estimates from SCD-HeFT, and the estimated differences in 5-year survival were similar 
between analyses. We believe the 3 sets of validation tests indicate that the resource use, 
cost, and survival estimates generated with the TEAM-HF model demonstrate respectable 
internal and external validity.
Variability
Across the simulations, we generally observed higher point estimates for costs and resource 
use when simulations were varied stochastically. This occurs because high counts (ie, 
outliers) of resource use are sometimes generated with stochastic sampling, which better 
represents empirical distributions of resource use. Thus, we expect that stochastic sampling 
will better represent variability that can be expected in real-world situations. In addition, 
recognition that costs and survival may substantially vary in cohorts with small sample sizes 
is important. The literature includes many small studies of disease management programs 
that reported cost savings over a short time period. Such findings could be attributable to 
one or more high-cost outliers in the comparison group and would not likely be replicated if 
the study was repeated. The TEAM-HF model could be used to evaluate whether observed 
differences in resource use, costs, and survival could be expected, given the impact of the 
disease management program on the prognostic factors represented in SHFM scores.
Limitations
Although we believe this model could prove to be a valuable resource, its users should be 
aware of its limitations. First, because HF-ACTION largely enrolled patients with NYHA 
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class II and III heart failure, the statistical relationships between SHFM scores and resource 
use and health utilities that are embedded in the model will be less precise for individuals 
with more advanced disease. Nevertheless, by integrating end-of-life costs incurred by 339 
HF-ACTION participants who died,15 our model incorporates high rates of resource use 
incurred during this period. In addition, resource use patterns in HF-ACTION may not be 
representative of other settings. Nevertheless, clinical sites in HF-ACTION included both 
academic and nonacademic institutions. Users should also recognize that the treatment 
effects for medications and devices embedded in the SHFM are based on randomized 
clinical trials. Therefore, when proportions of patients treated with evidence-based 
medications are modeled, those proportions should represent individuals who adhere to their 
treatments at a level similar to what would be observed in a clinical trial, not the proportions 
of patients prescribed specific medications. Lastly, although the SHFM offers several 
advantages, it does not include some variables found to be predictive of mortality in other 
prognostic models, such as B-type natriuretic peptide level.28
We plan to expand the model to incorporate other prognostic models to allow users to 
perform sensitivity analyses or choose the prognostic model that includes variables that best 
capture the intermediate effects of a given disease management program. In the near term, 
we hope that the model proves useful to researchers and health care managers in evaluating 
the costs and outcomes associated with disease management programs in heart failure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Survival Curves and Mean Survival Estimates for Integer Seattle Heart Failure Model 
Scores
SHFM Score (ζ)
−1 0 1 2 3
Expected survival, y 11.53 8.07 5.14 2.93 1.48
95% CI
 N = 100 (10.51–12.55) (7.22–8.92) (4.50–5.78) (2.51–3.35) (1.24–1.72)
 N = 1000 (11.21–11.85) (7.80–8.34) (4.94–5.34) (2.80–3.06) (1.40–1.56)
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Figure 2. 
Cause-Specific Hazard for Death (Upper Panel) and Cause-Specific Probability of Death 
(Conditional on Having Died at the Time Indicated by the Time Axis) as a Function of an 
Initial Seattle Heart Failure Model Score (Lower Panel)
Reed et al. Page 13
Am Heart J. Author manuscript; available in PMC 2016 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Reed et al. Page 14
Table 1
User-Defined Inputs for the TEAM-HF Cost-Effectiveness Model
Input Page Parameters (Options)
General information Scenario name
Scenario comments
Study design (parallel groups, single cohort, hypothetical)
Group name*
Group sample size*
Length of observation†
Observed resource use and death*† Counts of cardiovascular procedure-related hospitalizations; medically treated heart failure 
hospitalizations; non-heart failure hospitalizations; emergency department visits; outpatient visits
Number of patients who died
Clinical characteristics*‡ Age
Sex
Weight
New York Heart Association class
Systolic blood pressure
Ejection fraction
Ischemic failure etiology
Laboratory measurements*‡ Percent lymphocytes
Serum sodium
Total cholesterol
Hemoglobin
Uric acid
Diuretics*‡ Proportion of patients receiving diuretics, and daily doses for each of the following medications: 
furosemide, bumetanide, torsemide, metolazone, hydrochlorothiazide
Medications and devices*‡ Proportions of patients treated with β-blocker, aldosterone antagonist or potassium-sparing diuretic, 
ARB, ACE inhibitor, biventricular pacemaker, ICD, biventricular ICD
Unit costs Cost per month for β-blocker, aldosterone antagonist or potassium-sparing diuretic, ARB, ACE 
inhibitor, diuretic
Cost per event for cardiovascular procedure-related hospitalization, medically treated heart failure 
hospitalization, non-heart failure hospitalization, emergency department visit, outpatient visit
Disease management program 
characteristics
Time period for intense and maintenance phases of the program
Program cost per patient upon initiation
Program cost per patient per month during intense and maintenance phases of program
Simulation options Time horizon
Discount rates
Select output for resource use counts, costs, survival, and incremental cost-effectiveness ratios
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; ICD, implantable cardioverter-defibrillator.
*
Inputs for both the intervention and comparison groups.
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†
Applies to parallel group design only.
‡
Variables included in computation of Seattle Heart Failure Model scores.
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